Month: November 2025

Hong Kong - 2025年11月3日 - SeaPRwire，领先的新闻传播平台，推出了一款创新的虚拟新闻编辑助手，该系统由SeaPRwire与合作伙伴Asia Presswire (https:/asiapresswire.com)共同开发。该人工智能驱动的系统旨在辅助新闻编辑进行内容编辑和校对，提高编辑工作流程的效率和准确性。 随着对高质量、无错误内容的需求不断增长，新闻机构和媒体开始越来越依赖技术来简化其编辑流程。传统的编辑和校对方法往往耗时且容易出现人为错误，尤其是在新闻内容量日益增加的情况下。SeaPRwire的虚拟新闻编辑助手通过提供一个自动化解决方案，利用人工智能帮助编辑快速而准确地优化新闻内容，从而解决了这一挑战。 "我们推出的虚拟新闻编辑助手对于希望提高编辑速度和精准度的新闻机构来说，是一次具有革命性的变革，"SeaPRwire客户支持总监Lucy Clark表示。"通过使用人工智能技术，系统可以高效地审查内容，纠正语法和句法错误，并提供增强新闻文章清晰度和流畅性的建议。它为新闻编辑提供了一个强大的工具，确保内容不仅准确，而且精致和专业。" 该系统通过分析新闻文章的结构和语言，识别潜在问题，例如拼写和语法错误、语气不一致或表达不自然。然后，它提供修正和改进的建议，允许编辑快速进行更改，而不妥协工作质量。这在节奏紧张、内容量大的环境中尤为重要。 "随着新闻机构在紧迫的截止日期下需生产高质量内容的压力不断增加，我们的虚拟新闻编辑助手提供了急需的支持，"Clark补充道。"该人工智能系统不仅帮助编辑捕捉他们可能忽视的错误，还提升了内容的可读性和专业性，这对于维护新闻机构的声誉至关重要。" 通过推出这一先进的工具，SeaPRwire旨在帮助新闻机构、媒体和公关专业人士提高编辑效率，同时保持高标准的质量和准确性。虚拟新闻编辑助手预计将减少手动校对和编辑的时间，让新闻编辑能够更多地专注于内容创作和策略。 虚拟新闻编辑助手的推出是SeaPRwire在为不断发展的媒体环境提供创新解决方案方面迈出的重要一步。通过自动化耗时的编辑任务，该系统帮助新闻机构在要求速度与质量并重的行业中保持竞争力。 SeaPRwire的这一新系统，借助Asia Presswire先进的人工智能技术，现已向多个行业和地区的用户开放，提供了一种智能高效的解决方案，以改善编辑工作流程并制作高质量的新闻内容。 关于Asia Presswire Asia Presswire (https:/asiapresswire.com) 是一家新闻稿发布服务公司，为全球公关公司、代理机构、组织和企业提供定制化解决方案。他们专注于提供定制化的新闻稿分发服务，包括通过电子邮件直接发送新闻稿给报纸、杂志和广播媒体编辑。其广泛的网络覆盖172个国家，连接超过230,000个媒体渠道以及360万个自媒体平台。Asia Presswire支持超过46种语言，包括英语、中文、法语、德语和日语，确保在多语言区域内实现有效沟通。其服务旨在提升品牌的在线可见性和声誉，有效地与目标受众建立联系。 关于SeaPRwire SeaPRwire是亚洲领先的媒体传播管理平台，旨在赋能公关和传播专业人士。其品牌洞察计划通过将客户与80,000多名记者、编辑、杂志和在线媒体平台连接，简化了传播管理，同时还与3亿多关键意见领袖（KOL）粉丝网络对接。借助AI技术，SeaPRwire帮助用户识别相关媒体和KOL，个性化推介内容，并衡量传播效果。SeaPRwire在包括日本、中国、韩国、香港、新加坡、越南、泰国、马来西亚、印度尼西亚和菲律宾等地区运营，有效提升品牌认知并教育受众。 媒体联系 Brand: SeaPRwire Contact: Media team Email: cs@seaprwire.com Website: https://seaprwire.com

Hong Kong – November 03, 2025 – SeaPRwire, a leading Public Relations Communication Platform, has launched an innovative Virtual News Editor Assistant, developed in collaboration with its partner Asia Presswire (https:/asiapresswire.com). This AI-powered system is designed to assist news editors with content editing and proofreading, enhancing both the efficiency and accuracy of editorial workflows. As the demand for high-quality, error-free content grows, news organizations and media outlets are increasingly relying on technology to streamline their editorial processes. Traditional methods of editing and proofreading can be time-consuming and prone to human error, especially with the ever-increasing volume of news content being produced. SeaPRwire’s Virtual News Editor Assistant addresses this challenge by offering an automated solution that leverages artificial intelligence to assist editors in refining news content quickly and accurately. “The launch of our Virtual News Editor Assistant is a game-changer for newsrooms looking to improve both speed and precision in their editorial processes,” said Lucy Clark, Customer Support Director at SeaPRwire. “By using AI technology, the system can efficiently review content, correct grammar and syntax errors, and provide suggestions to enhance the clarity and flow of news articles. It offers news editors a powerful tool to ensure their content is not only accurate but also polished and professional.” The system works by analyzing the structure and language of news articles, identifying potential issues such as spelling and grammatical mistakes, inconsistencies in tone, or awkward phrasing. It then provides suggestions for corrections and improvements, allowing editors to make changes quickly without compromising the quality of their work. This is especially valuable in fast-paced environments where deadlines are tight and the volume of content is high. “With the increasing pressure on newsrooms to produce high-quality content under tight deadlines, our Virtual News Editor Assistant provides much-needed support,” Clark added. “The AI-powered system not only helps editors catch mistakes they may have missed but also enhances the overall readability and professionalism of the content, which is crucial for maintaining the reputation of news organizations.” By offering this cutting-edge tool, SeaPRwire aims to help newsrooms, media outlets, and PR professionals improve their editorial efficiency while maintaining high standards of quality and accuracy. The Virtual News Editor Assistant is expected to reduce the time spent on manual proofreading and editing, allowing news editors to focus more on content creation and strategy. The introduction of the Virtual News Editor Assistant is a significant step in SeaPRwire’s ongoing efforts to provide innovative solutions for the evolving media landscape. By automating time-consuming editorial tasks, this system helps news organizations stay competitive in an industry that demands both speed and quality. SeaPRwire’s new system, powered by Asia Presswire’s advanced AI technology, is now available to users across various industries and regions, offering a smart and efficient solution for improving editorial workflows and producing high-quality news content. About Asia Presswire Asia Presswire (https:/asiapresswire.com) is a press release distribution service that provides tailored solutions for public relations firms, agencies, organizations, and corporations worldwide. They specialize in delivering customized press release distribution, including direct-to-editor email delivery to targeted media editors at newspapers, magazines, and broadcast outlets. Their extensive network spans 172 countries, connecting with over 230,000 media outlets and 3.6 million self-media platforms. Supporting over 46 languages, including English, Chinese, French, German, and Japanese, Asia Presswire ensures effective communication across diverse linguistic regions. Their services are designed to enhance brands’ online visibility and reputation, enabling effective connection with target audiences. About SeaPRwire SeaPRwire is a leading earned media communications management platform in Asia, designed to empower PR and communications professionals. Its Branding-Insight Program streamlines communication management by connecting clients with a network of over 80,000 journalists, editors, magazines, and online media outlets, along with 300 million followers of key opinion leaders (KOLs). Leveraging AI-driven technology, SeaPRwire enables users to identify relevant media and KOLs, personalize pitches, and measure the impact of their communications efforts. Operating across regions including Japan, China, Korea, Hong Kong, Singapore, Vietnam, Thailand, Malaysia, Indonesia, and the Philippines, SeaPRwire enhances brand awareness and educates audiences effectively. Media Contact Brand: SeaPRwire Contact: Media team Email: cs@seaprwire.com Website: https://seaprwire.com

SHENZHEN, Oct 30, 2025 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of CMS on 22 April 2025 for details) together with its subsidiaries, holds co-development rights (except for atopic dermatitis (AD)) and exclusive commercialization rights for the Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (“MG-K10” or the “Product”). The New Drug Application (“NDA”) has been accepted by National Medical Products Administration (“NMPA”) on 30 October 2025. The product is intended for the treatment of adult with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. MG-K10 (generic name: Comekibart Injection) is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13. With a longer half-life, the Product enables a four-week dosing frequency (currently marketed anti-IL-4Rα drugs require biweekly dosing), which is expected to improve patient adherence. MG-K10 is expected to become the world’s first long-acting anti-IL-4Rα monoclonal antibody to be launched on the market, and has the potential to become the Best-in-Class (BIC). MG-K10 has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical study in adults with moderate-to-severe AD, meeting the primary research endpoint as designed, and at 52 weeks of treatment with MG-K10, proportion of participants with Investigator Global Assessment (IGA) score of 0 or 1, also with an improvement of ≥2 points from baseline is 76.6%; proportion of participants with ≥75% reduction in Eczema Area and Severity Index (EASI 75) from baseline is 94.3 %; proportion of participants with ≥90% reduction in Eczema Area and Severity Index (EASI 90) from baseline is 79.1 %. Regarding safety, most of the Treatment Emergent Adverse Event (TEAE) were Grade 1-2, with no Adverse Event of Special Interest (AESI) or fatal adverse event occurred. The incidence of common adverse reactions (conjunctivitis, injection site reactions, etc.) of drugs with the same target is relatively low for MG-K10. The Product has the potential for the treatment of other type 2 inflammatory diseases, such as asthma, prurigo nodularis, seasonal allergic rhinitis, chronic obstructive pulmonary disease, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Among them, asthma, prurigo nodularis and seasonal allergic rhinitis have all entered the phase III clinical trial stage in China. If MG-K10 is approved, it will provide a new, effective, and safe systemic treatment option for 14.5 million patients with moderate-to-severe AD[1]. Furthermore, MG-K10 will generate synergy with Dermavon’s ruxolitinib cream (for mild to moderate AD), the oral small molecule TYK2 inhibitor CMS-D001 (for moderate to severe AD), and dermatology-grade skincare products of Heling soothing product series, establishing a comprehensive solution for AD that covers various administration routes (injection, oral, and topical) and addresses multiple needs in “treatment + care”, benefiting a wide range of AD patients. Concurrently, it will further enrich Dermavon’s product portfolio in the field of dermatological treatment and reinforce its leading position in skin health sector. On 24 January 2025, CMS through its subsidiaries entered into a Collaboration Agreement (“Agreement”) with Hunan Mabgeek Biotech Co., LTD and its subsidiaries for MG-K10. In accordance with the Agreement and supplementary agreements, CMS has obtained the co-development rights (excluding AD) and exclusive commercialization rights for the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore; its subsidiary Dermavon has obtained, through its subsidiary, the co-development rights (excluding AD) and exclusive commercialization rights for the Product in the field of dermatological indications in Mainland China. About AD Indication MG-K10’s first indication, AD, is a chronic inflammatory skin disease accompanied by severe itching. It is the most burdensome non-fatal skin disease worldwide and also a chronic disease with a relatively high prevalence and significant disease burden in China. It is estimated that there are over 54 million AD patients in China in 2024. Based on SCORAD scores, the proportion of moderate to severe AD in China was 27%, which means there are over 14.5 million patients[1]. Due to the limitations in efficacy and safety of traditional systemic therapies for AD, moderate to severe AD patients often experience delays in systemic treatment initiation, poor compliance, and suboptimal disease control, leaving a significant unmet need in clinical practice[2]. MG-K10, with its extended dosing interval of once every four weeks, is expected to improve patient adherence and provide a new, effective, and safe systemic treatment option for patients with moderate-to-severe AD. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference: 1. China Insights Consultancy. Industry report on global and China Dermatology Treatment and Care Industry 2. Chinese Society of Dermatology, China Dermatologist Association. Clinical pathway for the diagnosis and treatment of moderate to severe atopic dermatitis in China (2023): an expert consensus[J]. Chinese Journal of Dermatology, 2023, 56(11): 1000-1007. DOI: 10.35541/cjd.20230247. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/